Bayer’s Sevabertinib Gains First-Line FDA Approval in HER2-Mutant NSCLC

{
  "signal_id": "646e54a4-0bbb-cd6a-157e-c1b29dbfc3e8",
  "signal_type": "news",
  "signal_subtype": "launches",
  "detected_at": "2026-09-09T19:06:03+00:00",
  "company": {
    "name": "Bayer",
    "domain": "bayer.com"
  },
  "data": {
    "url": "https://www.securities.io/bayers-sevabertinib-gains-first-line-fda-approval-in-her2-mutant-nsclc/",
    "title": "Bayer’s Sevabertinib Gains First-Line FDA Approval in HER2-Mutant NSCLC - Securities.io",
    "excerpt": "Bayer announced on September 9, 2026, that the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib as a first-line treatment option for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test. According to the company, the decision follows FDA Priority Review and Breakthrough Therapy Designation for sevabertinib in this setting. Sevabertinib is an oral, reversible, small molecule tyrosine kinase inhibitor (TKI). Bayer states that the compound potently inhibits mutant HER2, including HER2 exon 20 insertions and HER2 point mutations, by blocking tyrosine kinases involved in the growth of cancer cells, and that reversible TKIs temporarily block their targets, which the company says allows more precise control over treatment and potentially reduces long-term side effects compared with irreversible TKIs. The drug originates from Bayer’s strategic research alliance with the Broad Institute of MIT and Harvard. The FDA approved the first-line indication under its accelerated approval pathway based on objective response rate (ORR) and duration of response (DOR) in a cohort of 69 treatment-naive patients in the ongoing Phase I/II SOHO-01 trial (NCT05099172), which is evaluating the efficacy and safety...",
    "product": "sevabertinib",
    "summary": "Bayer's drug, sevabertinib, received accelerated approval from the U.S. Food and Drug Administration (FDA) as a first-line treatment for adults with a specific type of HER2-mutant non-small cell lung cancer (NSCLC).",
    "location": "United States",
    "planning": false,
    "image_url": "https://www.securities.io/wp-content/uploads/2026/09/bayers-sevabertinib-gains-first-line-fda-approval-in-her2-mutant-nsclc.jpg",
    "confidence": 0.95,
    "product_data": {
      "name": "sevabertinib",
      "full_text": "sevabertinib",
      "fuzzy_match": false
    },
    "product_tags": [
      "medical"
    ],
    "published_at": "2026-09-09T19:06:03Z",
    "location_data": [
      {
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "effective_date": "2026-09-09",
    "article_sentence": "Bayer announced on September 9, 2026, that the U.S. Food and Drug Administration (FDA) granted accelerated approval to sevabertinib as a first-line treatment option for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.",
    "related_company_name": "U.S. Food and Drug Administration",
    "related_company_domain": "fda.gov"
  }
}

curl https://signals.autobound.ai/v1/signals/646e54a4-0bbb-cd6a-157e-c1b29dbfc3e8 \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"bayer.com","limit":20}'